Cancer-causing virus exploits key cell-survival proteins
- Date:
- February 23, 2011
- Source:
- Ohio State University Medical Center
- Summary:
- The human T-lymphotropic virus type 1, a cancer-causing retrovirus, exploits key proteins in host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study. The virus, which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that targets two important cell proteins, one involved in DNA damage repair, the other involved in the destruction of proteins within the cell.
- Share:
A cancer-causing retrovirus exploits key proteins in its host cells to extend the life of those cells, thereby prolonging its own survival and ability to spread, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) and Ohio State's College of Veterinary Medicine.
The human T-lymphotropic virus type-1 (HTLV-1), which causes adult T-cell leukemia and lymphoma, produces a protein called p30 that is essential for the retrovirus to establish an infection. This study found that this viral protein targets two important cell proteins: ATM, a key player in a cell's response to DNA damage, and REG-gamma, which marks proteins within the cell for destruction.
"Our findings suggest that the p30 viral protein prolongs the survival of host cells through this interaction with ATM and REG-gamma, and the longer a virus-infected cell survives, the better chance the virus has to spread, " says principal investigator Michael Lairmore, DVM, PhD, professor of veterinary biosciences and associate director for shared resources at the OSUCCC -- James.
The findings were published recently in the Journal of Biological Chemistry.
An estimated 20 million people worldwide are infected by HTLV-1, and about five percent of them will develop adult T-cell leukemia or lymphoma, or one of a variety of inflammatory disorders.
Lairmore and his colleagues used cell lines and a variety of biochemical assays to identify cellular binding partners of p30.
They discovered the following:
- p30 specifically binds to cellular ATM (ataxia-telangiectasia mutated), a key regulator of DNA damage responses and cell cycle control, and to REG-gamma, a nuclear proteasome activator.
- Under stressful conditions, p30 levels are associated with lower ATM levels and increased cell survival.
- The expression of p30 changes in concert with expression of REG-gamma, suggesting that overexpression of REG-gamma enhances levels of p30.
- p30 forms a complex with ATM and REG-gamma.
Funding from the National Cancer Institute supported this research.
Other Ohio State researchers involved in this study were Rajaneesh Anupam, Antara Datta, Matthew Kesic, Kari Green-Church, Nikolozi Shkriabai and Mamuka Kvaratskhelia.
Story Source:
Materials provided by Ohio State University Medical Center. Note: Content may be edited for style and length.
Journal Reference:
- Anupam R, Datta A, Kesic M, Green-Church K, Shkriabai N, Kvaratskhelia M, Lairmore MD. Human T-lymphotropic virus type 1 p30 interacts with REG{gamma} and modulates ataxia telangiectasia mutated to promote cell survival. J Biol Chem, 2011 Jan 7 [abstract]
Cite This Page: